GARDP and Entasis Therapeutics Initiate Global Phase 3 Trial of Zoliflodacin, a First-in-Class Oral Antibiotic for the Treatment of Gonorrhea Randomized, open label trial will assess the efficacy and safety of zoliflodacin versus a combination of azithromycin and ceftriaxone, the current standard of care87 million new gonorrhea infections...

Entasis Therapeutics Announces New Results Supporting Advancement of Multiple Pathogen-Targeted Antimicrobial Programs at ASM Microbe 2019 WALTHAM, Mass., June 27, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...